Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor‐α by inhibiting nuclear factor‐κB activation
- 1 April 2003
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (8) , 1571-1579
- https://doi.org/10.1038/sj.bjp.0705189
Abstract
1. The marine product cacospongionolide B, a sesterterpene isolated from the Mediterranean sponge Fasciospongia cavernosa, is an inhibitor of secretory phospholipase A(2) with anti-inflammatory properties. In this work, we have studied the mechanism of action of this compound in the inflammatory response induced by zymosan in primary cells and in the mouse air pouch. 2. In mouse peritoneal macrophages, cacospongionolide B was able to downregulate the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), resulting in decreased production of NO and prostaglandin E(2) (PGE(2)). This compound also reduced tumour necrosis factor-alpha (TNF-alpha) mRNA expression and TNF-alpha levels. 3. Cacospongionolide B inhibited nuclear factor-kappaB (NF-kappaB)-DNA binding activity and the nuclear translocation of this transcription factor. 4. Treatment of cells with cacospongionolide B impaired NF-kappaB inhibitory protein (IkappaB-alpha) phosphorylation and enhanced IkappaB-alpha expression. 5. Inhibition of iNOS, COX-2 and inflammatory mediators was confirmed in the mouse air pouch. 6. These results show that cacospongionolide B is able to control NO, PGE(2) and TNF-alpha production in vitro and in vivo, effects likely dependent on NF-kappaB inhibition.Keywords
This publication has 38 references indexed in Scilit:
- Molecular Mechanism of Tumor Necrosis Factor-α Production in 1→3-β-Glucan (Zymosan)-activated MacrophagesJournal of Biological Chemistry, 2001
- Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFκB in tumour necrosis factor productionAnnals of the Rheumatic Diseases, 2000
- NF-κB activationCritical Care Medicine, 2000
- Anti-Cytokine Therapy for Rheumatoid ArthritisAnnual Review of Medicine, 2000
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- Nitric oxide and inflammatory arthritidesLife Sciences, 1997
- Nuclear factor–kB in rheumatoid synovium. Localization of P50 and P65Arthritis & Rheumatism, 1995
- Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretionInternational Journal of Immunopharmacology, 1995
- Proinflammatory Cytokines Regulate Cyclooxygenase-2 mRNA Expression in Human MacrophagesBiochemical and Biophysical Research Communications, 1995
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992